Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in obesity in Greece
ACTRN12625000071426Phase 4Not yet recruiting
- Sponsor
- Hellenic Endocrine Network
- Start
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tirzepatide in obesity, sponsored by Hellenic Endocrine Network. Primary endpoints: Weight loss and Adverse effects related to tirzepatide at 12 months. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on ACTRN12625000071426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000071426.